InvestorsHub Logo
Followers 789
Posts 118176
Boards Moderated 19
Alias Born 09/05/2002

Re: DewDiligence post# 1135

Thursday, 05/25/2023 8:38:43 AM

Thursday, May 25, 2023 8:38:43 AM

Post# of 1161
Milvexian—>FDA Fast Track designation for_all_indications:

The three indications BMY is pursuing in phase-3 are: secondary stroke prevention; ACS; and primary stroke prevention in patients with AF.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BMY News